Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: risperidone (RISPERDAL CONSTA) Clear all
Completed No phase listed Observational

Long-term Antipsychotic Pediatric Safety Trial

NCT03522168
View directory record Official record
Conditions
Weight, Body
Interventions
Risperidone, Aripiprazole
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years to 18 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
37
States / cities
Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Not applicable Interventional Results available

Glucose and Lipid Metabolism on Antipsychotic Medication

NCT00515723
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
risperidone, olanzapine, quetiapine, ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

NCT00694707
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Cariprazine, Risperidone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions

NCT01222975
View directory record Official record
Conditions
Healthy
Interventions
Risperidone
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Sep 30, 2026, 2:34 AM EDT
Terminated Phase 4 Interventional

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

NCT00314613
View directory record Official record
Conditions
Schizophrenia
Interventions
Antipsychotic/Risperidone Consta
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Butner, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

NCT01175135
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-02545920, Placebo, Risperidone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Little Rock, Arkansas • Anaheim, California • Escondido, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

NCT01677377
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Little Rock, Alaska • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence

NCT00385801
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Risperidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02186769
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperdal® Consta®, LY03004
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Orange County, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Severe Childhood Aggression (The TOSCA Study)

NCT00796302
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
Drug · Behavioral
Lead sponsor
Michael Aman
Other
Eligibility
6 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

NCT00176202
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium, risperidone
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
10 Years to 20 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

NCT00206102
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine fumarate, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
63
States / cities
Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional

A Study of Risperidone Monotherapy in Bipolar Anxiety

NCT00167479
View directory record Official record
Conditions
Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions
risperidone (Risperdal)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Tampa, Florida • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional

A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients

NCT01086748
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Placebo, LY2140023
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Escondido, California • Garden Grove, California • Paramount, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Recruiting Phase 4 Interventional

CLOZAPINE Response in Biotype-1

NCT04580134
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Interventions
clozapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

Antipsychotic Discontinuation in Alzheimer's Disease

NCT00417482
View directory record Official record
Conditions
Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
Interventions
risperidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Norwalk, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)

NCT01333072
View directory record Official record
Conditions
Autistic Disorder
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis

NCT01878513
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
Interventions
risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional

Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study

NCT00352196
View directory record Official record
Conditions
Asperger's Disorder
Interventions
Risperidone, Magnetic Resonance Spectroscopy
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
6 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Sep 30, 2026, 2:34 AM EDT